Omega Therapeutics, Inc.
NASDAQ:OMGA
1.22 (USD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 3.094 | 2.073 | 0.144 | 0 | 0 |
| Cost of Revenue
| 6.771 | 5.19 | 1.387 | 1.146 | 0.794 |
| Gross Profit
| -3.677 | -3.117 | -1.243 | -1.146 | -0.794 |
| Gross Profit Ratio
| -1.188 | -1.504 | -8.632 | 0 | 0 |
| Reseach & Development Expenses
| 77.169 | 79.996 | 47.865 | 21.063 | 11.931 |
| General & Administrative Expenses
| 26.186 | 21.821 | 16.603 | 6.236 | 4.227 |
| Selling & Marketing Expenses
| -6.771 | 0 | 0 | 0 | 0 |
| SG&A
| 19.415 | 21.821 | 16.603 | 6.236 | 4.227 |
| Other Expenses
| 0.023 | 3.022 | 1.708 | 1.346 | 1.181 |
| Operating Expenses
| 96.584 | 104.839 | 66.176 | 28.645 | 17.339 |
| Operating Income
| -100.261 | -102.766 | -66.032 | -28.645 | -17.339 |
| Operating Income Ratio
| -32.405 | -49.574 | -458.556 | 0 | 0 |
| Total Other Income Expenses Net
| 2.833 | 0.065 | -2.248 | -0.802 | -0.606 |
| Income Before Tax
| -97.428 | -102.701 | -68.28 | -29.447 | -17.945 |
| Income Before Tax Ratio
| -31.489 | -49.542 | -474.167 | 0 | 0 |
| Income Tax Expense
| 6.603 | -0.065 | 0.882 | 0.752 | 0.584 |
| Net Income
| -97.428 | -102.636 | -69.162 | -30.199 | -18.529 |
| Net Income Ratio
| -31.489 | -49.511 | -480.292 | 0 | 0 |
| EPS
| -1.8 | -2.14 | -1.45 | -0.63 | -0.39 |
| EPS Diluted
| -1.8 | -2.14 | -1.45 | -0.63 | -0.39 |
| EBITDA
| -93.49 | -102.766 | -64.673 | -27.524 | -16.556 |
| EBITDA Ratio
| -30.217 | -49.574 | -449.118 | 0 | 0 |